

**FOR IMMEDIATE RELEASE**

## **Analysis Group Releases Report on Impact of Authorized Generic Entry on Paragraph IV Certifications**

### **No Evidence of Decrease in Certifications Found**

---

**Boston, April 18, 2007** — Analysis Group, a leading provider of economic, financial, and business expertise to law firms, corporations, and government agencies, today released a self-published report entitled, “Do Authorized Generic Drugs Deter Paragraph IV Certifications? Recent Evidence.” The report, co-authored by [Ernst R. Berndt](#) of MIT’s Sloan School of Management and the National Bureau of Economic Research, [Richard Mortimer](#), a Vice President at Analysis Group, and [Andrew Parece](#), a Managing Principal at Analysis Group, found no evidence that paragraph IV certifications have declined in response to increased authorized generic entry. As a result, increased authorized generic entry has not resulted in delays to the timing of generic entry and, based on the authors’ earlier research, has instead benefited consumers through lower drug prices.

To determine the extent of the impact authorized generic entry had on paragraph IV certifications, the researchers examined three datasets on paragraph IV certifications: one compiled by the FDA; a second containing information based on a survey of The Pharmaceutical Research and Manufacturers of America (PhRMA) members; and the third containing information on court cases involving paragraph IV certifications.

The full report can be found on Analysis Group’s website.

[Analysis Group](#) ([www.analysisgroup.com](http://www.analysisgroup.com)) provides economic, financial, and business strategy consulting to leading law firms, Fortune 500 companies, and government agencies. The firm assists law firms with all aspects of litigation and advises corporations and government clients on business issues that require expert analysis and interpretation of economic and financial data. The firm helps corporations create strategies for innovation and growth.

Founded in 1981, with more than 350 professional staff, Analysis Group has offices in Boston, Chicago, Dallas, Denver, Los Angeles, Menlo Park, Montreal, New York, San Francisco, and Washington.

###